News | February 09, 2023
JB Pharma records revenue growth of 32% to Rs. 793 Cr in Q3 FY23
Profit after Tax stood at Rs. 106 crore as compared to Rs. 84 crore registering growth of 26%
Profit after Tax stood at Rs. 106 crore as compared to Rs. 84 crore registering growth of 26%
During the quarter, foreign exchange fluctuations had an impact of Rs. 4.56 crore Q3 FY23 Profit After Tax after considering exchange rate fluctuations stood at Rs. 8.2 crore
DETAF would be a welcome new addition in the management of HIV infections and will be available for supplies to low- and middle-income countries
Multilateral collaborations will serve to strengthen knowledge sharing to formulate framework for accessible, affordable, and quality healthcare
Valentas and Arnipin are indicated to reduce repeated hospitalization and the risk of cardiovascular death among adult patients with chronic mild to moderate heart failure
Dolutegravir and Rilpivirine Tablets, 50 mg/25 mg, (RLD Juluca) had estimated annual sales of US $666 million in the US (IQVIA MAT September 2022)
Under the soon to be launched Heal in India initiative, India aims to provide its health infrastructure for patients abroad and make it a global hub for medical and value-based healthcare for patients from across the world
Swiftmelt 1515-I meets performance requirements and secures skin attachment
ANSSI Wellness launches Asia’s premier and USA-patented ‘Spinal Decompression Treatment’ center in Nashik
The company has plans to launch this Vaccine by the end of 2023 after completing the required field studies and obtaining regulatory approvals
Subscribe To Our Newsletter & Stay Updated
